Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Oct 11;14(10):e0222885. doi: 10.1371/journal.pone.0222885

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Ganem et al

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PMC Copyright notice

Fig 2 — Survival curves using the Kaplan-Meier method. (a) PFS was longer for patients with low TLG₂ (HR = 2.8, 95%CI 1.3–5.9, p< 0.01). After 2 years, the survival rate was 67% for the 30 patients with low TLG₂ vs 34% for the 20 others. Median survival was respectively reached at 31 and 16 months. (b) 21 patients with high decrease of TLG after therapy (ΔTLG < -81%) showed longer OS (HR = 3.8, 95%CI 1.5–9.6, p = 0.02). After 1 year and after 2 years, survival rates for the 21 good responders were 91% versus 76% and 59% for the 29 bad responders. Median survival was not reached for good responders and was 29 months for the others. (c) Survival curves showed longer OS for patients with low TLG₂ (HR = 7.1, 95%CI 2.8–18, p< 0.01). After 2 years, the survival rate was 89% for the 21 patients with low TLG₂ (median survival not reached) vs 52% for the other 29 patients (median survival at 28 months).